Selank Dosing Guide: Research Protocols for the Russian Anxiolytic Nootropic Peptide

Selank is a synthetic heptapeptide developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences under the direction of Nikolai F. Myasoedov. Its sequence (Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP) extends the natural tetrapeptide Tuftsin with a stabilising Pro-Gly-Pro tail, shielding it from peptidase degradation. What makes Selank unusual among research peptides is its triple pharmacological profile: anxiolytic effects comparable in Russian trials to medazepam, cognitive-supportive nootropic activity, and measurable immunomodulation. This guide covers mechanism of action, pharmacokinetics, research dosing ranges, reconstitution math for intranasal delivery, and a head-to-head comparison with its sister peptide Semax, which researchers frequently confuse with Selank.

The information below reflects published research from Russian medical journals, Western PubMed-indexed papers, and manufacturer documentation as of 2026. Selank is not approved for human use in the European Union or the United States and is sold only for laboratory research. Everything that follows is written for that context.

What Is Selank?

Selank is a short peptide of molecular formula C33H57N11O9, molecular weight 751.90 g/mol, CAS registry number 129954-34-3. Chemically it is the N-terminal tetrapeptide Tuftsin (Thr-Lys-Pro-Arg), a fragment of the immunoglobulin G heavy chain, lengthened at the C-terminus with Pro-Gly-Pro. Tuftsin on its own has a plasma half-life measured in seconds because aminopeptidases cleave it rapidly. The Pro-Gly-Pro tail in Selank slows that degradation dramatically and also improves blood-brain-barrier permeability, which is why the compound is delivered intranasally rather than orally.

The peptide was designed in a state research programme aimed at finding benzodiazepine alternatives without sedation, cognitive dulling, or physical dependence. In Russia it is registered as Selank 0.15 percent nasal drops for generalised anxiety disorder and neurasthenia. Outside Russia, Selank remains an unlicensed investigational compound and is handled as a research chemical. It is supplied as a lyophilised white powder in 10 mg glass vials, typically at ≥99 percent purity by HPLC with mass spectrometric identity confirmation.

Because the parent Tuftsin sequence carries immunological activity, Selank retains part of that profile. This distinguishes it from most anxiolytics and from its more purely nootropic cousin Semax. Researchers interested in the peptide usually come to it for one of three questions: anxiety without sedation, cognitive performance under stress, or interferon-related immune modulation.

Mechanism of Action

Selank does not bind the benzodiazepine site on the GABA-A receptor. Instead, it acts as a positive allosteric modulator through a distinct site, producing GABAergic tone without the classical benzodiazepine profile of sedation, amnesia, and tolerance. Electrophysiological studies show enhanced inhibitory postsynaptic currents in hippocampal neurons after Selank exposure, an effect that can be blocked by bicuculline (a GABA-A antagonist) but is insensitive to flumazenil.

The peptide also modulates monoaminergic neurotransmission. Rodent studies from the Kozlovskaya and Semenova groups at the Institute of Molecular Genetics report increased 5-hydroxyindoleacetic acid (5-HIAA) to serotonin ratios in the hypothalamus and striatum, suggesting accelerated serotonin turnover rather than raw 5-HT elevation. Dopamine metabolism shifts in the same direction. These changes are consistent with the anxiolytic plus cognition-supporting behavioural phenotype observed in open-field, elevated plus maze, and Morris water maze paradigms.

Transcriptomic work by Kolomin, Shadrina, Slominsky, and Limborska extended the picture. Single intranasal doses of Selank produce measurable upregulation of BDNF and NGF messenger RNA in the hippocampus within hours, and differential expression of hundreds of genes involved in neuronal plasticity and inflammation. Separately, Selank inhibits enkephalin-degrading enzymes, prolonging the half-life of endogenous enkephalins, which contributes to its anti-stress effect.

Immunomodulatory arm

The Tuftsin fragment inside Selank is biologically active in its own right on macrophages and neutrophils. Uchakina and colleagues documented cytokine shifts in human leukocyte cultures exposed to Selank, including induction of type I and type II interferons. Russian influenza prophylaxis protocols from the 2000s used intranasal Selank alongside or in place of standard prophylactic antivirals, with reduced morbidity reported in field studies. Western replication of these specific immune findings is limited.

Pharmacokinetics and Half-Life

Selank is given intranasally because oral bioavailability is effectively zero, gastric peptidases destroy the molecule before absorption. Intranasal delivery bypasses this and provides partial direct nose-to-brain transport through olfactory and trigeminal pathways, in addition to systemic absorption across the nasal mucosa.

The parent peptide has a plasma half-life of only 2 to 3 minutes. That number looks discouraging in isolation, but the behavioural and biochemical effects last orders of magnitude longer. Three mechanisms explain this mismatch. First, the Pro-Gly-Pro tail is enzymatically cleaved to release active metabolites, including Tuftsin-like fragments that retain GABAergic and immunomodulatory activity. Second, the downstream gene-expression effects (BDNF, NGF, cytokine modulation) unfold over hours and persist after the peptide has cleared. Third, the inhibition of enkephalinases produces a sustained elevation of endogenous opioid-peptide tone.

In practical research-protocol terms this means the parent-peptide half-life is irrelevant for dosing frequency decisions. Most published Russian protocols use a single morning dose or split doses across a day, not because blood levels need to be maintained but because the downstream signalling windows suggest once- or twice-daily pulses are sufficient. Reported cerebrospinal fluid penetration is rapid after intranasal dosing, with peak CSF concentrations within approximately 30 minutes.

Research Evidence

The largest body of Selank literature sits in Russian-language psychiatric journals, particularly the S. S. Korsakov Journal of Neurology and Psychiatry. The key anxiolytic trial, Zozulya and colleagues (2001), compared intranasal Selank against the benzodiazepine medazepam in patients with generalised anxiety disorder and neurasthenia. Selank produced anxiolytic efficacy comparable to medazepam on standard rating scales but without sedation, cognitive impairment on psychomotor tests, or withdrawal symptoms after discontinuation.

Medvedev and collaborators (2007, 2014) extended this work in larger cohorts, reporting similar efficacy and an improvement in attention and working memory under anxiety load, an effect benzodiazepines cannot match. The composite picture from these Russian trials is a compound that lowers anxiety while preserving or even supporting cognition, at doses of 1.5 to 2.25 mg total daily (delivered as 0.15 percent nasal drops, 2 to 3 drops per nostril, three times daily).

Preclinical evidence is broader. Semenova, Kozlovskaya, and colleagues documented anxiolytic effects in elevated plus maze and open-field tests in rats across strains, with dose-response curves suggesting a therapeutic window between 100 and 1000 mcg per kilogram intraperitoneally. Neuroprotective signals appear in ischemia-reperfusion models, hypoxia tolerance studies, and six-hydroxydopamine-lesion rat models, although in the latter, Semax typically outperforms Selank on pure neuroprotection endpoints.

Outside Russia, peer-reviewed replication is sparse. There are no completed Food and Drug Administration or European Medicines Agency registered clinical trials of Selank, which is why the compound is classified as investigational in the European Union. Anecdotal reports from biohacker communities (Longecity, r/Nootropics) are widespread but fall well below the evidence threshold that a pharmacology chapter would require.

Research Dosing Protocols

Published Russian protocols and established research-community practice converge on a dose range of 250 to 500 micrograms per administration, one to three times daily, delivered intranasally. The total daily dose in research-grade protocols typically sits between 500 and 1500 mcg, rarely higher. This is the central Selank dosing window referenced throughout the literature and is the figure researchers use when planning in-vitro or animal-equivalent protocols.

Three common dosing schedules appear in documented research settings:

Single morning dose. 250 to 500 mcg once daily, usually in the morning on an empty stomach. This mirrors the simplest Russian out-patient protocol and provides all-day anxiolytic coverage thanks to the long downstream signalling tail.

Twice-daily split. 250 mcg in the morning and 250 mcg in the early afternoon. Used in protocols where sustained cognition under load is the endpoint, for example in combined anxiety and attention studies.

Russian GAD protocol. 300 to 900 mcg three times daily as 0.15 percent nasal drops, continued for 14 days. This is the highest of the three schedules and reflects the registered anxiolytic indication in Russia.

A titration rationale is straightforward. Researchers typically start at 250 mcg once daily for the first 2 to 3 days to characterise response and nasal tolerability, then move to the target schedule. There is no published evidence that doses above 1500 mcg daily produce additional benefit, and higher doses are generally avoided in the research literature.

Dose-by-question framing

In research planning, the question dictates the dose. Anxiety-dominant studies tend to use 250 to 500 mcg once or twice daily. Attention-under-stress studies use a morning plus early-afternoon split, typically 250 mcg each. Immunomodulation studies, reflecting Russian influenza prophylaxis work, use 300 mcg three times daily for 5 to 7 days. Peptide sourcing from research-grade Selank with HPLC analysis is the baseline assumption for any of these protocols, since purity below 99 percent introduces confounding impurities that will show up in cytokine or BDNF readouts.

Reconstitution and Intranasal Delivery

Selank arrives as a lyophilised white powder in a 10 mg glass vial with a rubber septum. It is reconstituted with bacteriostatic water (BAC water, 0.9 percent benzyl alcohol as preservative) and transferred into a metered-dose nasal spray bottle. Critically, Selank is not injected. A BD MICRO-FINE insulin syringe may be used only as a transfer tool to draw BAC water, inject it into the vial, and then withdraw the reconstituted solution into the spray bottle. The end-use device is the spray pump, not a needle.

Three common reconstitution volumes produce three different dose-per-spray targets. A standard metered-dose pharmaceutical spray actuates approximately 0.1 ml (100 microlitres) per pump, which means ten sprays empty one millilitre of solution.

Reconstitution options for a 10 mg Selank vial

2 ml BAC water. Final concentration 5 mg/ml. At 0.1 ml per spray, each spray delivers 500 mcg. The vial yields 20 doses. Use this concentration when the target research dose is 500 mcg per administration.

4 ml BAC water. Final concentration 2.5 mg/ml. Each spray delivers 250 mcg. The vial yields 40 doses. This is the most common configuration in documented research protocols because 250 mcg aligns with both the single-dose and twice-daily schedules.

10 ml BAC water. Final concentration 1 mg/ml. Each spray delivers 100 mcg. The vial yields 100 doses. Used when a more granular dose-response design is required, or when the researcher wants to deliver 200 to 300 mcg in clean 100 mcg increments.

Procedure

Wipe the vial septum with an alcohol swab. Draw the planned BAC water volume with a transfer syringe, insert the needle at a shallow angle, and direct the stream down the vial wall rather than onto the peptide cake. Swirl gently to dissolve, never shake. Peptide hydrogen bonds are fragile and vigorous agitation can denature the molecule. Once dissolved, draw the solution back into the transfer syringe or a sterile pipette and dispense into a primed 5 to 10 ml metered-dose spray bottle, typically amber PET or glass. Prime the pump with 2 to 3 actuations into a tissue until a fine mist appears, then store upright refrigerated at 2 to 8 degrees Celsius.

Reconstituted Selank is stable for 28 days at 2 to 8 degrees Celsius under BAC-water preservation. For multi-dose protocols beyond 28 days, reconstitute a fresh vial and discard the previous solution. Alternate nostrils when a dose exceeds one spray. Lyophilised vials are stable for 24 months at minus 20 degrees Celsius, approximately 12 months at 2 to 8 degrees, and about 6 months at room temperature if sealed.

Selank vs Semax

Both peptides were developed at the Institute of Molecular Genetics under the same programme, and both share a Pro-Gly-Pro C-terminal stabiliser. That is where the similarity ends. Researchers who select the wrong one for a given question waste a study.

Parameter	Selank (TKPRPGP)	Semax (MEHFPGP)
Parent motif	Tuftsin (IgG heavy chain fragment)	ACTH 4-7 fragment
Molecular weight	751.90 g/mol	813.93 g/mol
Primary profile	Anxiolytic, immunomodulatory	Neurotrophic, nootropic, neuroprotective
Russian registered use	GAD, neurasthenia	Ischaemic stroke, optic nerve atrophy
GABA-A interaction	Yes, allosteric modulation	Minimal
BDNF/NGF upregulation	Moderate	Strong, central to its profile
Immune activity	Yes, cytokine and interferon induction	Minimal
Typical dose	250 to 500 mcg intranasal, 1 to 3 x daily	250 to 1000 mcg intranasal, 1 to 3 x daily

In plain terms: if the research question is anxiety, stress tolerance, or immune modulation, Selank is the correct tool. If the question is neuroprotection, post-stroke recovery, or cognitive performance in non-anxious subjects, Semax is the better fit. The two peptides are not interchangeable and should not be stacked without a clear rationale.

Side Effects and Safety Profile

Published Russian human trials report a benign side-effect profile relative to benzodiazepines or SSRIs. The most commonly noted adverse event is transient nasal irritation, occasional mild headache, and rare dysgeusia (metallic taste) during or shortly after administration. Sedation, cognitive impairment, respiratory depression, and withdrawal syndromes characteristic of benzodiazepine anxiolytics are not observed in the Russian clinical literature.

Preclinical acute toxicity is low; reported rodent LD50 values sit above 500 mg/kg intraperitoneally, more than three orders of magnitude above a human-equivalent research dose. No reproductive toxicity or teratogenicity has been reported in the available Russian preclinical dossier, but Western long-term human safety data beyond 30 days do not exist. Interactions with SSRIs, SNRIs, or benzodiazepines are undercharacterised, and researchers designing combination studies should treat the interaction space as unmapped.

COA-certified Selank from Bergdorf Bio and comparable ≥99 percent HPLC-verified sources minimise adverse events attributable to impurities. Research-use-only product is shipped in sealed lyophilised vials and should not be administered if the powder shows moisture, yellowing, or incomplete reconstitution.

Sourcing and Quality Markers

A trustworthy Selank supplier provides a Certificate of Analysis (CoA) with every batch. The CoA should list the product name and full sequence, lot number, molecular formula, molecular weight, HPLC chromatogram with explicit percent purity, mass spectrometry identity confirmation (expected [M+H]+ at m/z 752.9), Karl Fischer water content, acetate counter-ion content, appearance, manufacture date, retest date, and the signature of the quality-control analyst.

Purity at or above 99 percent by HPLC is the research standard. Below 99 percent, truncated or deletion sequences appear that can bind the same receptors with different efficacy, producing noisy data. For immune or transcriptomic endpoints, endotoxin testing (below 0.25 EU per mg) is additionally relevant since lipopolysaccharide contamination will drive cytokine readouts regardless of the peptide itself. Lyophilized Selank ≥99% purity from suppliers that publish batch-level CoAs is the baseline assumption in most research protocols.

Researchers investigating overlapping respiratory-immune questions often pair peptide work with clinical-grade diagnostic tooling, and our respiratory and influenza rapid test collection is used by several groups for baseline morbidity screens during influenza-season protocols.

Frequently Asked Questions

What is the typical research dose of Selank?

Research protocols use 250 to 500 mcg intranasally, one to three times daily. Total daily doses range between 500 and 1500 mcg in published Russian clinical work.

Why is Selank given intranasally and not by injection?

Oral bioavailability is effectively zero because gastric peptidases destroy the peptide. Intranasal delivery bypasses first-pass degradation and adds a partial nose-to-brain route through olfactory and trigeminal pathways. Subcutaneous injection is not the established research route for this peptide.

How long does one Selank vial last?

A 10 mg vial reconstituted at 2.5 mg/ml yields 40 sprays of 250 mcg each. At twice-daily dosing this covers 20 research days, at once-daily dosing 40 days. Reconstituted solution in BAC water is stable for 28 days refrigerated, which is the binding limit for a single reconstitution.

What is the half-life of Selank?

The parent peptide has a plasma half-life of 2 to 3 minutes. Downstream effects via active metabolites, gene-expression changes, and enkephalinase inhibition persist for hours to days, which is why dosing frequency is set by downstream windows rather than plasma kinetics.

Is Selank addictive like benzodiazepines?

Russian clinical data report no withdrawal syndrome, no tolerance escalation, and no rebound anxiety after discontinuation. Mechanistically, Selank does not engage the benzodiazepine binding site on GABA-A, which is the molecular basis of benzodiazepine dependence.

Can Selank and Semax be combined?

Some bodybuilder and nootropic community protocols stack the two. Published research on combined administration is minimal. The peptides have overlapping but distinct mechanisms and researchers should treat combination as an uncharacterised design rather than an established protocol.

What does Tuftsin analog mean?

Tuftsin is the natural tetrapeptide Thr-Lys-Pro-Arg derived from the Fc portion of immunoglobulin G and active on macrophages and neutrophils. Selank is Tuftsin with a Pro-Gly-Pro tail added, which protects it from peptidases and makes central activity possible.

Is Selank legal to purchase?

In the European Union and United States, Selank is unlicensed for human use and is sold exclusively as a research chemical. In Russia, it is registered as a 0.15 percent nasal drop product for generalised anxiety disorder. Researchers outside Russia should verify local rules before ordering.

How should Selank be stored?

Lyophilised vials are stable at minus 20 degrees Celsius for 24 months, 2 to 8 degrees for approximately 12 months, and room temperature for 6 months if sealed. Reconstituted solution in BAC water is stable at 2 to 8 degrees for 28 days.

Can the BD MICRO-FINE insulin syringe be used for Selank?

Only as a transfer tool during reconstitution, to move BAC water into the vial and then move reconstituted solution into the spray bottle. Selank is not injected. The end-use device is a metered-dose nasal spray pump.

What purity level should a CoA show?

At least 99 percent by HPLC with mass spectrometric identity confirmation. Below 99 percent, truncated or deletion sequences can confound receptor pharmacology and immune readouts.

Is N-Acetyl-Selank the same as Selank?

No. N-Acetyl-Selank is an acetylated analog with different pharmacokinetics and slightly different receptor engagement. Research evidence for N-Acetyl-Selank is much thinner and the two should not be substituted in a protocol.

Conclusion

Selank is one of the most unusual research peptides in current circulation: a Russian-designed heptapeptide whose triple profile of anxiolytic, nootropic, and immunomodulatory activity does not cleanly map onto any Western pharmacology category. Its intranasal delivery, low-milligram dosing, and long downstream effect despite a minute-scale plasma half-life make protocol design distinctive. For research teams studying anxiety without sedation, attention under stress, or cytokine modulation, the published evidence base is sufficient to plan a coherent study. What it is not, under any EU or US regulatory framework, is an approved medicine for human use. Treat it accordingly.

Medical Disclaimer

This blog post is for informational purposes only and is not a substitute for professional medical advice. Selank is an experimental peptide and is not approved for human use in many countries, including the member states of the European Union and the United States. Use outside of clinical trials or approved indications is illegal in many jurisdictions.

All information regarding dosages, protocols, and applications is based on available research and user reports, but may be inaccurate or incomplete. Individual responses and safety profiles can vary significantly, and long-term human safety data beyond 30 days do not exist in the peer-reviewed literature.

Before using Selank or any other peptide, consult a physician or healthcare professional. This article does not endorse off-label or illegal use of Selank. The author and parahealth assume no liability for side effects, injuries, or adverse events arising from the use of information discussed in this article.

For research purposes only. Not intended for human consumption.